MARKSANS

Marksans Pharma Ltd. announced on May 27, 2026, that it has uploaded the audio recording of its investor/analyst conference call on the Q4 FY26 financial results to its company website, as per Regulation 30 of SEBI LODR Regulations, 2015.

Consolidated Revenue ₹856.1 Cr vs ₹708.5 Cr (▲20.8% YoY), EBITDA ₹195.4 Cr vs ₹126.9 Cr (▲54.0% YoY), PAT ₹149.0 Cr vs ₹90.7 Cr (▲64.3% YoY). EBITDA Margin 22.8% vs 17.9% (▲490 bps).

Marksans Pharma Ltd. announced that its Board of Directors approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The Statutory Auditors have issued an unmodified opinion on these results. Additionally, the Board recommended a final dividend of Rs. 0.90 per equity share (90%) for the financial year 2025-26, subject to shareholder approval at the upcoming AGM.

Consolidated Revenue ₹856.11 Cr vs ₹708.46 Cr (▲20.84% YoY), EBITDA ₹195.42 Cr vs ₹126.94 Cr (▲53.95% YoY), PAT ₹149.03 Cr vs ₹90.73 Cr (▲64.26% YoY). EBITDA Margin 22.83% vs 17.92% (▲491bps). The Board also recommended a final dividend of ₹0.90 per equity share (90%) for FY2025-26.

Marksans Pharma Ltd. announced the grant of 3,00,000 (Three Lakh) stock options to eligible employees under the Marksans Employees Stock Option Scheme 2024 on May 25, 2026. The options have an exercise price of Rs. 10/- per stock option, a vesting period of one year, and an exercise period of two years from the date of grant for vested options.

Marksans Pharma Ltd. announced an earnings conference call for analysts and investors on Wednesday, May 27, 2026, at 04:30 PM (IST). The call is scheduled to discuss the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026. Management speakers will include Mr. Mark Saldanha (CMD) and Mr. Jitendra Sharma (CFO).